2020
Clinic-Based Pediatric Disclosure Intervention Trial Improves Pediatric HIV Status Disclosure in Ghana.
Paintsil E, Kyriakides TC, Antwi S, Renner L, Nichols JS, Amissah K, Kusah JT, Alhassan A, Ofori IP, Catlin AC, Gan G, Lartey M, Reynolds NR. Clinic-Based Pediatric Disclosure Intervention Trial Improves Pediatric HIV Status Disclosure in Ghana. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 84: 122-131. PMID: 32049772, PMCID: PMC7138721, DOI: 10.1097/qai.0000000000002316.Peer-Reviewed Original ResearchConceptsTreatment groupsHIV disclosure interventionsHIV health careHIV-positive childrenMultivariate Cox modelDisclosure interventionHIV status disclosureBetter overall treatment effectHealth care providersYears of ageChild-caregiver dyadsOverall treatment effectModified intentionHIV clinicHIV statusIntervention armIntervention trialsStatus disclosureTreat approachCare providersCox modelTime pointsTherapeutic communicationControl participantsHealth care
2018
Prevalence and correlates of depression among caregivers of children living with HIV in Ghana: findings from the Sankofa pediatric disclosure study
Ofori-Atta A, Reynolds NR, Antwi S, Renner L, Nichols JS, Lartey M, Amissah K, Tettey JK, Alhassan A, Ofori IP, Catlin AC, Gan G, Kyriakides TC, Paintsil E, Team O. Prevalence and correlates of depression among caregivers of children living with HIV in Ghana: findings from the Sankofa pediatric disclosure study. AIDS Care 2018, 31: 283-292. PMID: 30360643, PMCID: PMC6382516, DOI: 10.1080/09540121.2018.1537463.Peer-Reviewed Original ResearchConceptsCaregivers of childrenCaregiver depressionCaregivers of HIVLow HIV knowledgeChild health outcomesCorrelates of depressionLow social supportPediatric HIVIllness perceptionsIntervention trialsMean ageHIV knowledgeRisk factorsSevere depressionHigh prevalenceHIV stigmaAdjusted modelHIVCaregiver statusHealth outcomesStudy participantsCaregiversPrevalenceDepressionSub-Saharan countriesHigh prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana
Nichols JS, Kyriakides TC, Antwi S, Renner L, Lartey M, Seaneke OA, Obeng R, Catlin AC, Gan G, Reynolds NR, Paintsil E, Team O. High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana. AIDS Care 2018, 31: 25-34. PMID: 30235940, PMCID: PMC6288009, DOI: 10.1080/09540121.2018.1524113.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherence ratesPediatric HIV carePrevalence of adherenceAntiretroviral medication adherenceCohort of childrenHIV-positive statusChildren of caregiversChild-caregiver dyadsHIV carePharmacy recordsRefill dataMedian adherenceMedication adherenceAdherence ratesPoor adherenceHigh prevalencePositive statusIntervention studiesHIVGood adherenceAdherenceBaseline dataChildrenTherapyEfficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2016
Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study
Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedViral LoadViremiaConceptsVirologic failureViral load levelsPill burdenAlcohol useHuman immunodeficiency virus (HIV) careLow-level HIV viremiaUndetectable viral load levelsAntiretroviral regimen changesAntiretroviral therapy changesExperienced virologic failureLow-level viremiaIntravenous drug useSubset of patientsFrequent clinic visitsPoor clinical outcomePossible risk factorsHepatitis C virusHIV viremiaMore comorbiditiesNonfailure groupVirologic suppressionVirological failureCD4 countConsecutive chartsClinic visitsThe design and implementation of a randomized controlled trial of a risk reduction and human immunodeficiency virus prevention videogame intervention in minority adolescents: PlayForward: Elm City Stories
Fiellin LE, Kyriakides TC, Hieftje KD, Pendergrass TM, Duncan LR, Dziura JD, Sawyer BG, Fiellin DA. The design and implementation of a randomized controlled trial of a risk reduction and human immunodeficiency virus prevention videogame intervention in minority adolescents: PlayForward: Elm City Stories. Clinical Trials 2016, 13: 400-408. PMID: 27013483, PMCID: PMC4942329, DOI: 10.1177/1740774516637871.Peer-Reviewed Original ResearchConceptsGame dataHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus prevention interventionsPsychosocial antecedentsImmunodeficiency virus infectionRisk behavior reductionVideogame interventionMinority adolescentsBehavioral interventionsRisky sexual behaviorLarge-scale trialsMinority youthControl gameCommunity-based programsPeer pressureAssessment dataSummer campStudy visitBehavior reductionVirus infectionPrevention interventionsGame designersSchool programsAdolescentsEmpiric testing
2015
Sankofa pediatric HIV disclosure intervention cyber data management: building capacity in a resource-limited setting and ensuring data quality
Catlin AC, Fernando S, Gamage R, Renner L, Antwi S, Tettey JK, Amisah KA, Kyriakides T, Cong X, Reynolds NR, Paintsil E. Sankofa pediatric HIV disclosure intervention cyber data management: building capacity in a resource-limited setting and ensuring data quality. AIDS Care 2015, 27: 99-107. PMID: 26616131, PMCID: PMC4704410, DOI: 10.1080/09540121.2015.1023246.Peer-Reviewed Original ResearchConceptsCyber infrastructureData explorationOpen-source software platformData elementsData management toolsReal-time supportChallenges of capturingData management teamDatabase accessAccess controlData queryData management capacityDatabase systemsSoftware platformData managementAnalysis needsError checkingSummary viewCommon data elementsData captureData capture toolCapture toolClinical research dataData validationData summariesHIV knowledge, stigma, and illness beliefs among pediatric caregivers in Ghana who have not disclosed their child's HIV status
Paintsil E, Renner L, Antwi S, Dame J, Enimil A, Ofori-Atta A, Alhassan A, Ofori IP, Cong X, Kyriakides T, Reynolds NR. HIV knowledge, stigma, and illness beliefs among pediatric caregivers in Ghana who have not disclosed their child's HIV status. AIDS Care 2015, 27: 18-27. PMID: 26616122, PMCID: PMC4665118, DOI: 10.1080/09540121.2015.1007116.Peer-Reviewed Original ResearchConceptsHIV statusIllness perceptionsUsual careHIV knowledgeTeaching hospitalCaregiver characteristicsBrief HIV Knowledge QuestionnaireKorle-Bu Teaching HospitalKomfo Anokye Teaching HospitalBrief Illness Perception QuestionnaireMultivariable linear regression analysisCaregivers' illness perceptionsChild's HIV statusHigh HIV stigmaHIV Knowledge QuestionnaireMajority of HIVPercent of caregiversHIV-negative statusPediatric HIV disclosureIllness Perception QuestionnaireHIV-positive statusHIV Stigma ScaleBaseline dataLower household incomeMedian age
2011
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J, . Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLOS ONE 2011, 6: e14764. PMID: 21483491, PMCID: PMC3069000, DOI: 10.1371/journal.pone.0014764.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsDrug Resistance, Multiple, ViralFemaleHIV InfectionsHumansMaleMiddle AgedConceptsRe-treatment optionsART interruptionHIV infectionPrimary outcomeRetreatment optionsMultidrug resistanceAdvanced HIV diseaseAntiretroviral treatment interruptionARV treatment failurePrior AIDS diagnosisResistant HIV InfectionMedian CD4 countPrimary composite outcomeSerious adverse eventsMean viral loadBest medical managementOPTIMA trialCD4 countOpen labelTreatment interruptionAdverse eventsComposite outcomeFirst AIDSHIV diseaseAntiretroviral treatmentEffect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV
Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV. Medical Decision Making 2011, 32: 70-82. PMID: 21383086, DOI: 10.1177/0272989x10397615.Peer-Reviewed Original ResearchConceptsVisual analog scaleHIV patientsART intensificationTreatment interruptionClinical eventsMedical Outcomes Study HIV Health SurveyAdvanced HIV patientsAntiretroviral therapy interruptionMultiple treatment failuresTemporary treatment interruptionAdverse clinical eventsHealth-related qualityStandard ARTHealth Utilities IndexStandard gambleQuality of lifeAdvanced HIVART interruptionInferior HRQoLMDR HIVTherapy interruptionAntiretroviral therapyHIV cohortOpen labelHRQoL scores
2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 160-166. PMID: 20130473, DOI: 10.1097/qai.0b013e3181cbd235.Peer-Reviewed Original ResearchConceptsTreatment-naive populationTreatment-experienced patientsCD mutationsTreatment-experienced populationsHIV viral loadConnection domainConnection domain mutationsOPTIMA trialVirologic outcomesVirologic responseARV regimenARV therapyViral loadAntiretroviral drugsAntiretroviral trialsUnivariate analysisDiminished responseFrequency of mutationsMultivariate analysisPatientsReduced susceptibilityA371VDomain mutationsResistance phenotypeTrials
2009
Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST. Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 631-639. PMID: 19430303, DOI: 10.1097/qai.0b013e3181a4f00d.Peer-Reviewed Original ResearchConceptsSerious adverse eventsLate-stage HIV/AIDSAdvanced HIV/AIDSHIV/AIDSAdverse eventsMedical Outcomes Study HIV Health SurveyMental health summary scoresEffect of ADEMultidrug-resistant HIVHealth-related qualityHealth summary scoresQuality of lifePatients' HRQOLMultivariate linear regression modelRegular followHRQOL measuresTreatment strategiesEQ-5DHealth SurveyHRQoLImmune diseasesSummary scoresPatientsStudy sample populationAIDSHealth-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease
Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Owens DK. Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 27-36. PMID: 19295332, DOI: 10.1097/qai.0b013e31818ce6f3.Peer-Reviewed Original ResearchConceptsHealth Utilities Index Mark 3Treatment-experienced HIV patientsEQ-5DHIV patientsHRQoL scoresClinical variablesMedical Outcomes Study HIV Health SurveyEQ-5D visual analog scaleHealth statusStandard gamblePreference-based health-related qualityAdvanced HIV diseaseBaseline HRQOL scoresConcomitant medication useTreatment-experienced HIVCD4 cell countHIV viral loadHealth-related qualityVisual analog scaleVeterans Affairs hospitalEQ-5D VASCross-sectional studyPreference-based HRQOLQuality of lifeTime trade-off (TTO) technique
2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar time
2004
Study conduct, monitoring and data management in a trinational trial: the OPTIMA model
Kyriakides TC, Babiker A, Singer J, Piaseczny M, Russo J. Study conduct, monitoring and data management in a trinational trial: the OPTIMA model. Clinical Trials 2004, 1: 277-281. PMID: 16279253, DOI: 10.1191/1740774504cn022oa.Peer-Reviewed Original Research
2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B, Team O. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Contemporary Clinical Trials 2003, 24: 481-500. PMID: 12865041, DOI: 10.1016/s0197-2456(03)00029-1.Peer-Reviewed Original ResearchConceptsOPTIMA trialClinical trialsTherapeutic strategiesHuman immunodeficiency virus-infected individualsVirus-infected individualsDrug-free periodVeterans Affairs hospitalDifferent therapeutic strategiesYears of intakeNovel therapeutic strategiesAnti-HIV drugsAntiretroviral therapyStrategy armART drugsTrial designHIV drugsStudy durationHospitalTrialsRelative efficacyDrugsTherapyOptimum trial designYearsMulticenter
2002
Surveillance of HIV in the army of the Republic of Cyprus (SHARC); rationale, design, and implementation of an inexpensive system
Kyriakides T, Eleftheriou A, Michaelides N, Papantoniou L. Surveillance of HIV in the army of the Republic of Cyprus (SHARC); rationale, design, and implementation of an inexpensive system. Sexually Transmitted Infections 2002, 78: 50. PMID: 11872860, PMCID: PMC1763710, DOI: 10.1136/sti.78.1.50.Peer-Reviewed Original ResearchConceptsCross-sectional prevalence surveyResidual bloodSurveillance of HIVHIV Surveillance SystemHIV infection ratesABO blood groupHepatitis testingUseful epidemiological informationHIV incidenceHIV surveysInfection surveillanceHIV epidemicPrevalence surveyInfection ratePrevalence dataEpidemiological informationSurveillance projectBlood groupBloodSurveillance systemSurveillanceHIVPrevalenceIncidenceIntake
2001
Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther supportTiming of Antiretroviral Treatment Initiation
Kyriakides T, Guarino P. Timing of Antiretroviral Treatment Initiation. JAMA 2001, 285: 1702-1703. PMID: 11277817, DOI: 10.1001/jama.285.13.1702.Peer-Reviewed Original Research
1999
HIV-1 Transmission in Injection Paraphernalia: Heating Drug Solutions May Inactivate HIV-1
Clatts M, Heimer R, Abdala N, Goldsamt L, Sotheran J, Anderson K, Gallo T, Hoffer L, Luciano P, Kyriakides T. HIV-1 Transmission in Injection Paraphernalia: Heating Drug Solutions May Inactivate HIV-1. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 22: 194-199. PMID: 10843535, DOI: 10.1097/00126334-199910010-00013.Peer-Reviewed Original Research